Variables | Vedolizumab | Ustekinumab | Tofacitinib |
---|---|---|---|
(n = 65, 69.2%) | (n = 16, 17.0%) | (n = 13, 13.8%) | |
Headache | 1 | ||
Paraesthesia | 1 | 1 | |
Pruritus | 3 | ||
Rash | 2 | ||
Arthralgia | 1 | 1 | |
Herpes zoster | 2 | ||
Flu or flu-like illness | 1 | 1 | 1 |
Rhinitis | 1 | ||
Oral infection | 1 | ||
Urinary tract infection | 1 | ||
Adverse event total | 11 (16.9) | 3 (18.8) | 4 (30.8) |